A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

Cancer

Volumn 85, Issue 12, 1999, Pages 2532-2540

  Lévi, Francis ^a,j   Zidani, Rachid ^a   Brienza, Silvano ^b   Dogliotti, Luigi ^c   Perpoint, Bruno ^d   Rotarski, Mathieu ^b   Letourneau, Yves ^e   Llory, Jean François ^f   Chollet, Philippe ^g   Le Rol, Annick ^h   Focan, Christian ⁱ  

^a HÔPITAL PAUL BROUSSE   (France)

^b DEBIOPHARM SA   (Switzerland)

^c UNIVERSITY OF TURIN   (Italy)

^d SERVICE DE NEUROLOGIE   (France)

^e Centre Hospitalier Régional   (Canada)

^f Clinique Hartmann   (France)

^g CENTRE JEAN PERRIN   (France)

^h Hop du Perpétuel Secours   (France)

ⁱ Hopital St Joseph   (Belgium)

^j Lab 'Rythmes Biologiques C   (France)

more..

Author keywords

5 fluorouracil; Ambulatory; Chronotherapy; Circadian; Colorectal carcinoma; Delivery systems; Dose intensity; Leucovorin; Multicenter trial; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEPATOMEGALY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS;

EID: 0039276846     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1     Document Type: Article

References (24)

1. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
2. Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst 1994;86:1608-17.
3. Lévi F, Zidani R, Misset JL, for the International Organization for Cancer Chronotherapy. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350: 681-6.
4. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 1993;53:2816-22.
5. Boughattas N, Lévi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res 1989;49:3362-8.
6. Metzger G, Massari C, Etienne MC, Commisso M, Brienza S, Touitou Y, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharmacol Ther 1994;56: 190-201.
7. Smaaland R, Laerum OD, Lote K, Sletvold O, Bjerknes R, Lote K. DNA synthesis in human bonne marrow is circadian stage dependent. Blood 1991;77:2603-11.
8. Smaaland R, Laerum OD, Sothern RB, Sletvold O, Bjerknes R, Lote K. Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 1992;79: 2281-7.
9. Buchi KN, Moore JG, Hrushesky WJM, Sothern RB, Rubin NH. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 1991;101:410-5.
10. Lévi F. Chronotherapy for gastrointestinal cancers. Curr Opin Oncol 1996;8:334-41.
11. Brienza S, Lévi F, Valori V, Berthcault-Cuitkovic F, Defrés-Brummer P, Lecouturier S, et al. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1993;12:197.
12. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés-Brummer P, Brienza S, Adam R, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996;14(11):2950-8.
13. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT, Holman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: J.B. Lippincott, 1988:121-42.
14. Longo DL, Duffey PL, De Vita VT, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991; 9:2042-51.
15. Simon R. Design and conduct of clinical trials. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer. Principles and practice of oncology, 4th ed, chapter 19. Philadelphia: Lippincott, 1993:418-41.
16. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) Proc Am Soc Clin Oncol 1997;16:805.
17. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224(4):509-22.
18. Giacchetti S, Itzhaki M, Zidani R. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliflatin and surgery. Am Oncol 1999, 10 (in press).
19. Cunnigham D, Zalcberg JR, Rath U, Oliver I, Van Cutsem E, Svensson C, et al. Final results of a randomized trial comparing "Tomudex" (raltitrexel) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7/9: 961-5.
20. De Gramont A, Basset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997;15(2):808-15.
21. Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, et al. Prospectively randomized north central cancer treatment group trial of intensive-course fluorouracil combined with the 1-isomer of intravenous leucovorin, oral leucovorin or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997;15:3320-9.
22. De Gramont A, Figer A, Seymour M, Homerin M, Le Bail N, Cassidy J, et al. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:985.
23. Buyse M, Molenberghs G. Criteria for the validation of surrogate end-points in randomized experiments. Biometrics 1998;54:1014-29.
24. Lévi F, Zidani R, Giacchetti S, Llory JF, Dogliotti L, Perpoint B, et al. First line chemotherapy with 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (1-OHP) (FLO) against metastatic colorectal cancer (MCC): relationship between chronotherapy, dose intensity (DI), response and survival. Proc Am Soc Clin Oncol 1998;17:1044.